The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151.
Prologis
PLD · a US exchange · USD · Market cap $126.5B · 2,802 employees
Prologis, Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price128.67 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.11)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $103.02 to $118.47, base estimate $103.02 (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning political buying, disclosed 2026-10-15
- Options put/call open interest 2.11, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Prologis holds its Accumulation at $128.67. Consolidating, no directional conviction, held for 344 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 344 days |
| Price at the screen | $128.67 |
| Valuation | 28.66 trailing · 36.11 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.29 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 36.14% | Below 33% | Interest-bearing debt is 36.1% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 11.24% | Below 33% | Cash held in interest-bearing accounts and securities is 11.2% of assets, under the one-third limit. | Pass |
| Receivables | 1.77% | Below 49% | Money owed to the company is 1.8% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Prologis's business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PLD's ethical verdict changes
Today PLD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $103.02 fair value estimate, narrow competitive moat, 10.20% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 24.9% above the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +18% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $103.02, with a range of $103.02 to $118.47, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 36.1x forward earnings, the price already runs ahead of the business. It trades 25% above our $103.02 fair value, so you would be buying at a premium, not a discount. The narrow moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 36.1xexpensive even after accounting for its growth |
| Trailing P/E | 28.7xa premium valuation |
| EPS, trailing | 4.54 |
| EPS, forward | 3.60 |
| Revenue growth | +10.2%steady growth |
| Profit margin | 43.1%highly profitable on every dollar of sales |
| Return on equity | 7.7%a modest return on shareholder capital |
| FCF yield | 4.49% |
| Dividend yield | 2.93% |
| Debt to equity | 0.62moderate, manageable leverage |
| Current ratio | 0.73below 1: short-term bills exceed liquid assets |
| Beta | 1.29moves a little more than the market |
| Short interest, float | 0.02% |
| 52-week range | 121.40 - 153.35 |
| Moat | NARROW |
| Market cap | $126.5B |
| Employees | 2,802 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePLD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. Since the last review it dropped out of the Titan Ethical 500.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (20 analysts) rates it buy, with a mean price target of $151. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Form 8.3 Prologis, Inc Yahoo Finance · 3d ago
- Form 8.3 Yahoo Finance · 3d ago
- Dimensional Fund Advisors Ltd. : Form 8.3 - PROLOGIS INC - Ordinary Shares Yahoo Finance · 3d ago
- What Could Tightening Supply Mean For Prologis (PLD) Through 2027? Yahoo Finance · 3d ago
- Prologis: Rents Must Climb 27% to Justify New Warehouses Yahoo Finance · 4d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-28 | PIANI OLIVIER | Director | 1,984 | $280,873 | |
| 2026-04-28 | KENNARD LYDIA H | Director | 1,984 | · | |
| 2026-04-28 | CONNOR JAMES B | Director | 1,984 | · | |
| 2026-04-28 | MODJTABAI AVID | Director | 1,984 | · | |
| 2026-04-28 | LYONS IRVING F III | Director | 43,825 | $6,202,552 | |
| 2026-04-28 | PIANI OLIVIER | Director | 1,984 | · | |
| 2026-03-31 | LETTER DANIEL | Chief Executive Officer | 16,000 | $160 | |
| 2026-03-26 | MOGHADAM HAMID R | Director | 1,019,089 | · | |
| 2026-03-09 | ANDRUS CARTER | Chief Operating Officer | 25,106 | $251 | |
| 2026-01-28 | SLUSSER SARAH ANN | Director | 111 | $12,631 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $144.07 | +1.5% | · | $1,015 | +1.5% |
| 2 months | $137.19 | +6.6% | · | $1,066 | +6.6% |
| 3 months | $130.85 | +11.8% | $1.07 | $1,126 | +12.6% |
| 6 months | $128.52 | +13.8% | $2.08 | $1,154 | +15.4% |
| 1 year | $105.81 | +38.2% | $4.10 | $1,421 | +42.1% |
| 2 years | $103.89 | +40.8% | $7.99 | $1,484 | +48.4% |
| 3 years | $110.25 | +32.6% | $11.56 | $1,431 | +43.1% |
| 5 years | $108.21 | +35.1% | $17.48 | $1,513 | +51.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PLD does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.